Dysfunction of E-cadherin and catenin has been linked to invasiveness and differentiation of tumors. This study aimed to characterize the expression of cadherins and catenins in early gastric carcinoma and their relationship to clinicopathologic characteristics and Helicobacter pylori infection. E-cadherin and α-, β- and γ-catenins were strongly expressed in normal epithelium but abnormal immunoreactivity of at least one of these four proteins was noted in 48 (90.6%) of 53 early gastric carcinomas. Only 5 cases with intestinal-type tumors had intact expression of E-cadherin and α-, β-, and γ-catenins. Abnormal immunoreactivity in the tumor tissue was observed in 18 patients (34.0%) for E-cadherin, in 35 (66.0%) for α-catenin, in 20 (37.7%) for β-catenin, and in 37 (69.8%) for γ-catenin. In diffuse-type tumors, abnormal expression of E-cadherin (60.9 vs. 13.3%, p < 0.0005), α-catenin (82.6 vs. 53.3%, p < 0.05) and γ-catenin (91.3 vs. 53.3%, p < 0.005) was more frequent than in the intestinal type. Ten tumors with lymph node metastasis showed a relatively higher frequency of abnormal expression of E-cadherin (70 vs. 25.6%, p < 0.05) but a lower frequency of abnormal expression of β-catenin (10 vs. 44.1%, p = 0.07) than those without metastasis. No significant association was found between cadherin/catenin expression and the depth of invasion or the H. pylori status. It was concluded that abnormal expression of E-cadherin and the catenin-mediated cell-cell adhesion system occurs frequently in early gastric carcinogenesis and may play an important role in the genesis of histologic differentiation and in the mode of metastasis of early gastric carcinomas.

Keywords:
E-cadherin, Catenin, Early gastric carcinoma, Clinicopathologic characteristics, Helicobacter pylori
1.
Frenetle PS, Wagner DD: Adhesion molecules. N Engl J Med 1996;334:1526–1529.
2.
Edelmann GM, Crossin KL: Cell adhesion molecules: Implications for a molecular histology. Annu Rev Biochem 1991;60:155–190.
3.
Behrens J, Mareel MM, Van Roy FM, Birchmeier W: Dissecting tumor cell invasion: Epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989;108:2435–2447.
4.
Takeichi M: Cadherins: A molecular family important in selective cell-cell adhesion. Annu Rev Biochem 1990;59:237–252.
5.
Hinck L, Nathke IS, Papkoff J, Nelson WJ: Dynamics of cadherin/catenin complex formation: Novel protein interactions and pathways of complex assembly. J Cell Biol 1994;125:1327–1340.
6.
Gumbiner B: Cell adhesion: The molecular basis of tissue architecture and morphogenesis. Cell 1996;84:345–357.
7.
Yap AS, Brieher WM, Gumbiner BM: Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol 1997;13:119–146.
8.
Guilford P: E-cadherin downregulation in cancer: Fuel on the fire? Mol Med Today 1999;5:172–177.
9.
Shiozaki H, Oka H, Inoue M, Tamura S, Monden M: E-cadherin mediated adhesion system in cancer cells. Cancer 1996;77:1605–1613.
10.
Hirohashi S: Inactivation of the E-cadherin-mediated cell adhesion system in human cancer. Am J Pathol 1998;153:333–339.
11.
Pignatelli M, Karayiannakis AJ, Noda M: E-cadherin/catenin complex in the gastrointestinal tract; in Halter F, Winton D, Wright NA (eds): The Gut as a Model in Cell and Molecular Biology. Dordrecht, Kluwer, 1997, pp 194–203.
12.
Parkin DM, Pisani P, Fearly J: Estimates of worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594–606.
13.
Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal type carcinoma. Acta Pathol Microbiol Scand 1965;64:31–49.
14.
Murakami T: Pathomorphological diagnosis: Definition and gross classification of early gastric cancer. Gann Monogr 1971;11:53–55.
15.
Tahara E: Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol 1993;119:265–272.
16.
Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing M: Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: Relationship with patient survival. Gastroenterology 1997;112:46–54.
17.
Blok P, Craanen ME, Dekker W, Tytgat GNJ: Loss of E-cadherin expression in early gastric cancer. Histopathology 1999;34:410–415.
18.
Blok P, Craanen ME, Offerhaus J, Dekker W, Kuipers EJ, Meuwissen SG, Tytgat GN: Molecular alterations in early gastric carcinomas: No apparent correlation with Helicobacter pylori status. Am J Clin Pathol 1999;111:241–247.
19.
Wu MS, Shun CT, Wang HP, Lee WJ, Sheu JC, Wang TH, Lin JT: Genetic alterations in gastric cancer: Relation to histological subtypes, tumor stage and Helicobacter pylori infection. Gastroenterology 1997;112:1457–1465.
20.
Shun CT, Wu MS, Lin JT, Lee WJ, Huang RL, Chuang SM: An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer. Hepatogastroenterology 1998;45:944–999.
21.
Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen-Dale AL: E-cadherin and α-, β-, and γ-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 1998;185:262–266.
22.
Jawhari A, Noda M, Farthing M, Pignatelli M: Abnormal expression and function of the E-cadherin-catenin complex in gastric carcinoma cell lines. Br J Cancer 1999;80:322–330.
23.
Mayer B, Johnson JP, Leitl F, Jauch KW, Heiss MM, Schildberg FW, Birchmeier W, Funke I: E-cadherin expression in primary and metastatic gastric cancer: Downregulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 1993;53:1690–1695.
24.
Shino Y, Watanabe A, Yamada Y, Tanse M, Yamada T, Matsuda M, Yamashita J, Tatsumi M, Miwa T, Nakano H: Clinicopathological evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas. Cancer 1995;76:2193–2201.
25.
Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K, Aikou T: Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology 1999;57:131–137.
26.
Shiozaki H, Iihara K, Oka H, Kadowaki T, Matsui S, Gofuku J, Inoue M, Nagafuchi A, Tsukita S, Mori T: Immunohistochemical detection of alpha-catenin expression in human cancers. Am J Pathol 1994;144:667–674.
27.
Takayama T, Shiozaki H, Shibamoto S, Oka H, Kimura Y, Tamura S, Inoue M, Monden T, Ito F, Monden M: Beta-catenin expression in human cancers. Am J Pathol 1996;148:39–46.
28.
Valizadeh A, Karayiannakis AJ, El-Hariry I, Kmiot W, Pignatelli M: Expression of E-cadherin-associated molecules (α-, β-, and γ-catenins and p120) in colorectal polyps. Am J Pathol 1997;150:1977–1984.
29.
Hugh TJ, Dillon SA, Taylor BA, Pignatelli M, Poston GJ, Kinsella AR: Cadherin-catenin expression in primary colorectal cancer: A survival analysis. Br J Cancer 1999;80:1046–1051.
30.
Efstathiou JA, Pignatelli M: Modulation of epithelial cell adhesion in gastrointestinal homeostasis. Am J Pathol 1998;153:341–347.
31.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW: Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787–1790.
32.
Rubinfeld B, Albert I, Porfiri E, Munemitsu S, Polakis P: Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res 1997;57:4624–4630.
33.
Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguro S, Nakamura Y, Miyoshi Y: Activation of β-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 1998;58:1021–1026.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.